Ryan Bosch, MD, FACP, founder and president of Socially Determined, outlines steps for improving health literacy.
Earlier this month, the Biden administration announced it will commit $250 million in funding to improve COVID-19 vaccine health literacy in vulnerable and medically underserved communities. With the logistics of administering vaccines no longer an overwhelming question mark and an ample supply of doses available, vaccine hesitancy has quickly emerged as one of the biggest hurdles to overcoming the pandemic. In fact, polling from the Kaiser Family Foundation shows that 17% of Americans still want to “wait and see” before getting vaccinated, and that figure increases to 24% among Black Americans.
Vaccine hesitancy among vulnerable and medically underserved communities is especially concerning, as these populations have the greatest risk of contracting and becoming severely ill with COVID-19. For some, vaccine hesitancy is an understandable result of a lack of trust in the US health care system, brought on by past negative experiences and systemic inequities. For others, the hesitation can be attributed to low health literacy (ie, having insufficient capacity to obtain, process or understand the information needed to make decisions about healthcare).
COVID-19 has illuminated the dangerous implications of low health literacy among vulnerable and underserved communities, leading health care payers, providers and pharmaceutical organizations to begin paying more attention to the impact social and cultural disparities have on health outcomes. As a result, many are working to implement social determinants of health (SDOH) programs. Focused on improving education around the health care process and how to navigate the care journey, these programs work to establish relationships of trust to increase community understanding, buy-in and productive, collective action.
An increased emphasis on the impact social risk has on health and wellbeing is certainly welcomed and well-timed and improving health literacy can serve as a valuable social amplifier to any and all SDOH programs. Still, despite the fact that SDOH can drive up to 80% of health outcomes, a recent study from The Root Cause Coalition revealed that 52% of Americans have never heard of the term "social determinants of health" and just 21% know what it means.Fewer understand the tangible actions they can take to address their individual SDOH or the SDOH of their community as a whole.
With little individual or community understanding of SDOH, the onus is on organizations to take action to improve health literacy, because ultimately this is how SDOH programs will succeed in addressing critical health disparities for the long haul. Best practices for remedying health literacy at scale include listening to individuals, as opposed to talking at them. Persuading them shouldn’t be accomplished verbally, but rather in the form of action, and by communicating information with care. Furthermore, by serving as an example in the community of individual action (within the context of a community’s needs), organizations can help the individuals they serve better determine who and what to trust.
Tactically, there are 5 sequential steps to take to improve health literacy in a meaningful way, including:
Now more than ever, our country’s health care system has a timely and profound opportunity to intervene on SDOH by improving health literacy levels via a targeted, 5-step continuum. By following this process and implementing social risk analytics solutions from companies like Socially Determined, health care payers, providers and pharmaceutical organizations can repair lagging health literacy levels and use improved health literacy as the lever to amplify the positive impact of SDOH programs at scale.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
2 Commerce Drive
Cranbury, NJ 08512